Aloe Therapeutics develops Allo-Immunotherapy (AIM), a cell-based in situ vaccine that is implanted directly at the tumor site to enhance immune cell infiltration and convert "cold" tumors into "hot" tumors. AIM is designed to improve the efficacy of checkpoint inhibitor therapies and expand treatment options for patients with hard-to-treat solid tumors.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors are immunologically "cold," meaning they lack sufficient immune cell infiltration, which limits the effectiveness of checkpoint inhibitor therapies. Patients with these tumors often have limited treatment options and poor prognoses.
Solution
Aloe Therapeutics is developing Allo-Immunotherapy (AIM), an allogeneic, cell-based in situ vaccine designed to convert "cold" tumors into "hot" tumors by enhancing immune cell infiltration at the tumor site. AIM is delivered directly to the tumor, where it triggers inflammation and attracts immune cells, effectively rebooting the immune system's anti-tumor activity. This approach aims to improve the efficacy of checkpoint inhibitor therapies and expand treatment options for patients with hard-to-treat solid tumors, including recurrent, metastatic, and unresectable cancers. AIM is designed to remain at the tumor site for extended exposure and activity and can be easily integrated into existing treatment regimens without systemic toxicity.
Target Audience
The primary target audience includes oncologists and patients with advanced solid tumors who are not responding to existing therapies, as well as pharmaceutical companies developing checkpoint inhibitor therapies.
Features
- Off-the-shelf, allogeneic cell-based therapy, eliminating the need for complex cell engineering or patient-specific customization
- Localized delivery directly to the tumor site during biopsy or resection surgery
- Designed to induce a transplant rejection immune response, stimulating a strong influx of activated immune cells
- Broad application across various solid tumor types and disease stages, including "cold," recurrent, and metastatic tumors
- Potential for re-dosing to induce a prime/boost effect, further enhancing the immune response
- No requirement for patient lymphodepletion, simplifying the treatment process